Becton, Dickinson and Company $BDX Shares Sold by HB Wealth Management LLC

Key Points

• HB Wealth Management LLC has reduced its stake in Becton, Dickinson and Company (BDX) by 16.3% during the second quarter, now holding approximately $3.96 million in shares.
• Despite the recent sell-off by some investors, institutional ownership remains high, with 86.97% of BDX stock owned by institutional investors and hedge funds.
• Becton, Dickinson and Company reported an earnings per share (EPS) of $3.68 for the last quarter, exceeding analyst expectations, and has set its FY 2025 EPS guidance at 14.300-14.450.

HB Wealth Management LLC trimmed its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 16.3% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 22,972 shares of the medical instruments supplier's stock after selling 4,473 shares during the quarter. HB Wealth Management LLC's holdings in Becton, Dickinson and Company were worth $3,957,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in BDX. Brighton Jones LLC raised its holdings in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after acquiring an additional 877 shares during the last quarter. Versant Capital Management Inc increased its stake in Becton, Dickinson and Company by 27.4% in the first quarter. Versant Capital Management Inc now owns 265 shares of the medical instruments supplier's stock valued at $61,000 after purchasing an additional 57 shares during the last quarter. NBC Securities Inc. acquired a new position in Becton, Dickinson and Company in the first quarter valued at $102,000. Merit Financial Group LLC increased its stake in Becton, Dickinson and Company by 54.3% in the first quarter. Merit Financial Group LLC now owns 5,846 shares of the medical instruments supplier's stock valued at $1,339,000 after purchasing an additional 2,058 shares during the last quarter. Finally, Whipplewood Advisors LLC increased its stake in Becton, Dickinson and Company by 67.9% in the first quarter. Whipplewood Advisors LLC now owns 880 shares of the medical instruments supplier's stock valued at $202,000 after purchasing an additional 356 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

BDX stock opened at $190.90 on Thursday. The stock has a 50-day moving average price of $188.71 and a two-hundred day moving average price of $188.20. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The company has a market cap of $54.72 billion, a PE ratio of 34.33, a price-to-earnings-growth ratio of 1.51 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. During the same quarter in the previous year, the business earned $3.50 earnings per share. The firm's quarterly revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were given a $1.04 dividend. The ex-dividend date of this dividend was Monday, September 8th. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio is presently 74.82%.

Insider Activity

In other news, EVP Michael David Garrison sold 1,185 shares of the company's stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares of the company's stock, valued at $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Claire Fraser sold 917 shares of the company's stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares of the company's stock, valued at $4,167,375. The trade was a 3.96% decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,023 shares of company stock valued at $562,036 in the last ninety days. Company insiders own 0.36% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on BDX shares. Morgan Stanley upped their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Royal Bank Of Canada started coverage on Becton, Dickinson and Company in a research note on Thursday, September 25th. They issued a "sector perform" rating and a $211.00 target price for the company. Piper Sandler reiterated a "neutral" rating and issued a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Wells Fargo & Company upped their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research note on Friday, August 8th. Finally, Argus boosted their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Three analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $205.40.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.